Revised Announcement for Allotment of Equity Shares and Warrants on Preferential Basis.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals has allotted 6,44,360 equity shares at ₹1,250 per share (including a premium of ₹1,240) on a preferential basis, raising about ₹80.55 crore in cash. Alongside this, the company issued 5,51,600 convertible warrants at the same price of ₹1,250 each, with 25% (₹312.50) paid upfront, bringing in an additional ₹17.24 crore now and a potential ₹68.95 crore more on conversion within 18 months. The allotments were made to 62 investors, including the promoter group (MD Fredun Nariman Medhora and Daulat Nariman Medhora) and several institutional and HNI names such as Alchemy Capital Management, Alchemy Long Term Ventures Fund, Capri Global Holdings, NAV Capital VCC, and NavBharat Investment Trust. The securities are subject to SEBI ICDR lock-in restrictions, and BSE had already given its in-principle approval on December 19, 2025.
The preferential allotment meaningfully expands the company's equity base and brings in fresh long-term capital, but it also dilutes existing shareholders since most allottees are non-promoters. Promoters participating via warrants signals continued skin in the game, though full warrant conversion over the next 18 months could lead to further dilution.